
Location sensitive CAR-T cells target childhood brain tumors in early tests
Medical scientists engineered immune cells that remain dormant until reaching brain tissue, where they target aggressive tumor cells. Preclinical trials demonstrated full tumor elimination in animal models without widespread side effects.
The Blend
Scientists at the University of California, San Francisco have engineered a specialized form of cell therapy designed to switch on only after reaching brain tissue. According to a report from ScienceDaily on research published in Science Translational Medicine, these modified immune cells successfully eliminated an aggressive form of childhood brain cancer in laboratory mice. The technique relies on a protein native to the brain to trigger the treatment, keeping the engineered cells dormant while traveling through the rest of the body.
Diffuse midline glioma is among the most challenging pediatric cancers, often growing in sensitive areas that govern vital functions like breathing and heart rate. Standard treatments rarely stop its progression, and traditional immune cell therapies frequently cause severe side effects when activated outside the target organ. By utilizing a location-based switch, researchers may have unlocked a method to safely deliver targeted cancer treatments into delicate neural tissue without damaging other organs.
While the mouse studies demonstrated complete tumor clearance and lasting protection against recurrence, it is still unclear whether human brains will respond with the same level of safety and effectiveness. Researchers at UCSF Health plan to launch early clinical trials with human patients in 2027. An essential question moving forward is whether tumor cells could eventually evolve to bypass this activation mechanism, or if the brain's internal environment might change over time as a pediatric patient grows.
Written independently by AI News Smoothie from the reporting listed below. Facts belong to the original publishers. Follow the links for their full coverage.
Ingredients
- Scientists wipe out deadly brain tumors in every mouse tested with new cancer therapy | ScienceDaily
Engineered immune cells that activate only inside brain tissue successfully eliminated deadly pediatric brain tumors in mouse models, paving the way for human clinical trials.